Douglas Lazarus

3.3k citations

38 papers · 2.7k indexed · 1 hit paper · h-index 20

Molecular Biology top 5%
Oncology top 5%
Hematology top 2%
Immunology top 10%
Cancer Research top 5%

Co-authors: Antonia T. Destree Peter J. Elliott Julian Adams Vito J. Palombella Christine Pien J I Johnson Edward A. Sausville Jochen Maas
Topics: Cancer, Hypoxia, and Metabolism (9 papers)Nanoplatforms for cancer theranostics (7 papers)Growth Hormone and Insulin-like Growth Factors (6 papers)
Cited by: Hematology Oncology Cancer Research
Journals: Proceedings of the National Academy of Sciences Blood The Journal of Immunology
Partner nations: United States Canada Spain

In The Last Decade

Douglas Lazarus

36 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1999 1.2k citations Julian Adams, Vito J. Palombella et al. PubMed profile →

Peers

Countries citing papers authored by Douglas Lazarus

Since Specialization

Citations

This map shows the geographic impact of Douglas Lazarus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Lazarus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Lazarus more than expected).

Fields of papers citing papers by Douglas Lazarus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Lazarus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Lazarus. The network helps show where Douglas Lazarus may publish in the future.

Co-authorship network of co-authors of Douglas Lazarus

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Lazarus. A scholar is included among the top collaborators of Douglas Lazarus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Lazarus. Douglas Lazarus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 548: The microRNA-10b targeted therapeutic, TTX-MC138, is effective in preclinical pancreatic adenocarcinoma 2023 ·Cancer Research ·Subrata Ghosh,Douglas Lazarus,Neil Robertson,(unknown),Peter P. Liu,Zdravka Medarova	6
2	Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer 2016 ·Cancer Research ·Elizabeth Pham,Melissa Yin,Christian Peters,Christina R. Lee,Donna M. Brown,Ping Xu,Shan Man,Lata Jayaraman,Ellen Rohde,Annabelle Chow,Douglas Lazarus,Scott Eliasof,F. Stuart Foster,Robert S. Kerbel	55
3	CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer 2015 ·Breast Cancer Research and Treatment ·Sarah J. Conley,(unknown),Joseph Burnett,(unknown),Douglas Lazarus,Christian Peters,Shawn G. Clouthier,Scott Eliasof,Max S. Wicha	55
4	Abstract B176: In vitro and in vivo studies demonstrating sustained drug release for multiple anticancer payloads and improved anticancer effects of a cabazitaxel β-cyclodextrin-PEG copolymer-based nanoparticle-drug conjugate (NDC) 2015 ·Molecular Cancer Therapeutics ·Chester A. Metcalf,Donna Brown,Jungyeon Hwang,(unknown),Douglas Lazarus,Pochi Shum,Snehlata Tripathi,Scott Eliasof	1
5	Abstract B37: Selective tumor localization of CRLX101, a novel nanoparticle-drug conjugate 2015 ·Molecular Cancer Therapeutics ·Christian Peters,Douglas Lazarus,Donna M. Brown,Ningning Zhang,(unknown),Ellen Rohde,Scott Eliasof,Lata Jayaraman	2
6	Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer 2014 ·Clinical Cancer Research ·Elizabeth Pham,Michael J. Birrer,Scott Eliasof,Edward G. Garmey,Douglas Lazarus,Christina R. Lee,Shan Man,Ursula A. Matulonis,Christian Peters,Ping Xu,Carolyn Krasner,Robert S. Kerbel	77
7	An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis 2008 ·Inflammation Research ·Douglas Lazarus,(unknown),(unknown),(unknown),Matthew Labenski,James Wakefield,Russell Karp,(unknown),(unknown),Jennifer Hoyt,Charles D. Thompson,Gerhard Hannig,William Westlin	11
8	Aplidin® combination with chemotherapeutic agents in human melanoma tumors 2006 ·Doreen LePage,Douglas Lazarus,Mariano J. Elices,Wendy Grant,Halina Sasak,(unknown),(unknown),(unknown),(unknown),Carmen Cuevas,Pablo Avilés,Glynn Faircloth	1
9	A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis 2004 ·Proceedings of the National Academy of Sciences ·Sylvie G. Bernier,Douglas Lazarus,(unknown),(unknown),Matthew Labenski,Charles D. Thompson,William Westlin,Gerhard Hannig	84
10	Interleukin-1α (IL-1α) and Tumor Necrosis Factor α (TNFα) Regulate Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Levels and mRNA AbundanceIn VivoandIn Vitro* 1999 ·Hormone and Metabolic Research ·Carlos Benbassat,Douglas Lazarus,(unknown),T. M. Evans,Lyle L. Moldawer,S F Lowry,(unknown)	41
11	Proteasome inhibitors: a novel class of potent and effective antitumor agents.breakdown → 1999 ·PubMed ·Julian Adams,Vito J. Palombella,Edward A. Sausville,J I Johnson,Antonia T. Destree,Douglas Lazarus,Jochen Maas,Christine Pien,(unknown),Peter J. Elliott	1188
12	Involvement of 26-kDa cell-associated TNF-α in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor 1997 ·The Journal of Immunology ·Carmen C. Solórzano,Riadh Ksontini,Jeffrey H. Pruitt,P. Hess,P. Edwards,Atsushi Kaibara,Amer Abouhamze,Troy Auffenberg,Richard E. Galardy,Jean‐Nicolas Vauthey,Edward M. Copeland,Carl K. Edwards,Gregory Y. Lauwers,Michael Clare‐Salzler,S L MacKay,Lyle L. Moldawer,Douglas Lazarus	74
13	The lack of an effect by insulin or insulin-like growth factor-1 in attenuating colon-26-mediated cancer cachexia 1996 ·Cancer Letters ·Douglas Lazarus,Taku Kambayashi,S F Lowry,Gideon Strassmann	22
14	Interleukin 1 binding to its type I, but not type II receptor, modulates the in vivo acute phase response 1995 ·Cytokine ·Hester S. A. Oldenburg,(unknown),Douglas Lazarus,(unknown),(unknown),R Chizzonite,S F Lowry,Lyle L. Moldawer	30
15	Endogenous interleukin-10 protects against death in septic peritonitis in mice 1994 ·Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) ·Tom van der Poll,(unknown),(unknown),Douglas Lazarus,C V Keogh,Lananh Nguyen,Michel Goldman,Lyle L. Moldawer,Stephen F. Lowry	3
16	Cachexia and the acute‐phase protein response in inflammation are regulated by interleukin‐6 1993 ·European Journal of Immunology ·Hester S. A. Oldenburg,Michael A. Rogy,Douglas Lazarus,Kimberly J. Van Zee,(unknown),R Chizzonite,Stephen F. Lowry,Lyle L. Moldawer	121
17	Impact of exogenous growth hormone on host preservation and tumor cell-cycle distribution in a rat sarcoma model 1991 ·Journal of Surgical Research ·(unknown),Craig S. Rock,Douglas Lazarus,Lisa Staiano‐Coico,Eva Fischer,Lyle L. Moldawer,Stephen F. Lowry	16
18	Acute effects of hypophysectomy and administration of pancreatic and thyroid hormones on circulating concentrations of somatomedin-C in young chickens: Relationship between growth hormone and somatomedin-C 1988 ·Domestic Animal Endocrinology ·Douglas Lazarus,Colin G. Scanes	23
19	Invited Comment: Use of Acetate in Total Parenteral Nutrition Solutions 1988 ·Journal of Parenteral and Enteral Nutrition ·Douglas Lazarus,T. Peter Stein	1
20	Postnatal changes in circulating concentrations of growth hormone, somatomedin C and thyroid hormones in pigs 1987 ·Domestic Animal Endocrinology ·Colin G. Scanes,Douglas Lazarus,(unknown),F. C. Buonomo,Rex L. Gilbreath	34

About Douglas Lazarus

Douglas Lazarus is a scholar working on Cancer Research, Endocrinology, Diabetes and Metabolism and Biotechnology, having authored 38 papers that have together received 2.7k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (9 papers), Nanoplatforms for cancer theranostics (7 papers) and Growth Hormone and Insulin-like Growth Factors (6 papers). The work is most often cited by research in Hematology (432 citations), Oncology (774 citations) and Cancer Research (399 citations). Douglas Lazarus has collaborated with scholars based in United States, Canada and Spain. Frequent co-authors include Antonia T. Destree, Peter J. Elliott, Julian Adams, Vito J. Palombella, Christine Pien, J I Johnson, Edward A. Sausville, Jochen Maas, Lyle L. Moldawer and S F Lowry. Their work appears in journals such as Proceedings of the National Academy of Sciences, Blood and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact